




Searching News Database: GvHD
HSMN NewsFeed - 12 Nov 2020
Synthetic Biologics Welcomes Senior Biotech Executive John Monahan, PhD, to Board of Directors
Synthetic Biologics Welcomes Senior Biotech Executive John Monahan, PhD, to Board of Directors
HSMN NewsFeed - 5 Sep 2017
FDA Grants Orphan Drug Status to Cellect's ApoGraft(TM) for Acute GvHD and Chronic GvHD
FDA Grants Orphan Drug Status to Cellect's ApoGraft(TM) for Acute GvHD and Chronic GvHD
HSMN NewsFeed - 30 May 2017
Array BioPharma and Bristol-Myers Squibb Announce Strategic Collaboration
Array BioPharma and Bristol-Myers Squibb Announce Strategic Collaboration
HSMN NewsFeed - 20 Jan 2017
Bristol-Myers Squibb Provides Regulatory Update in First-line Lung Cancer
Bristol-Myers Squibb Provides Regulatory Update in First-line Lung Cancer
HSMN NewsFeed - 1 Sep 2016
Kamada and Kedrion Seek FDA Approval of Human Rabies Immunoglobulin as a Post-Exposure Treatment
Kamada and Kedrion Seek FDA Approval of Human Rabies Immunoglobulin as a Post-Exposure Treatment
HSMN NewsFeed - 28 Dec 2015
Chimerix Announces Top-Line Results From Phase 3 SUPPRESS Trial of Brincidofovir
Chimerix Announces Top-Line Results From Phase 3 SUPPRESS Trial of Brincidofovir
HSMN NewsFeed - 18 Nov 2013
Kiadis Pharma Provides Positive Update on its Phase II Clinical Program with Blood Cancer Treatment ATIR(TM)
Kiadis Pharma Provides Positive Update on its Phase II Clinical Program with Blood Cancer Treatment ATIR(TM)
HSMN NewsFeed - 2 Jun 2011
Soligenix Appoints Joseph Warusz as Vice President of Administration and Controller
Soligenix Appoints Joseph Warusz as Vice President of Administration and Controller
HSMN NewsFeed - 21 Sep 2010
Athersys Receives Orphan Drug Designation for MultiStem in Graft vs. Host Disease
Athersys Receives Orphan Drug Designation for MultiStem in Graft vs. Host Disease
HSMN NewsFeed - 8 Sep 2009
Osiris Therapeutics Announces Preliminary Results for Prochymal Phase III GvHD Trials
Osiris Therapeutics Announces Preliminary Results for Prochymal Phase III GvHD Trials
HSMN NewsFeed - 29 Jun 2009
DOR BioPharma Announces Publication of orBec(R) Clinical Pulmonary Data in Bone Marrow Transplantation
DOR BioPharma Announces Publication of orBec(R) Clinical Pulmonary Data in Bone Marrow Transplantation
HSMN NewsFeed - 13 Mar 2009
DOR BioPharma Appoints Brian L. Hamilton, MD, PhD as Chief Medical Officer
DOR BioPharma Appoints Brian L. Hamilton, MD, PhD as Chief Medical Officer
HSMN NewsFeed - 12 Feb 2009
Osiris Reports Positive Two-Year Data on Stem Cell Treatment for Acute Myocardial Infarction
Osiris Reports Positive Two-Year Data on Stem Cell Treatment for Acute Myocardial Infarction
HSMN NewsFeed - 15 Jan 2009
Osiris Receives FDA Clearance to Broaden Prochymal Expanded Access Program
Osiris Receives FDA Clearance to Broaden Prochymal Expanded Access Program
HSMN NewsFeed - 15 Jan 2009
Osiris and FDA Reach Agreement on Submission of First Marketing Application for a Stem Cell Product
Osiris and FDA Reach Agreement on Submission of First Marketing Application for a Stem Cell Product
HSMN NewsFeed - 6 Jan 2009
DOR BioPharma Obtains Fast Track Designation for DOR201 in the Prevention of Acute Radiation Enteritis
DOR BioPharma Obtains Fast Track Designation for DOR201 in the Prevention of Acute Radiation Enteritis
HSMN NewsFeed - 22 May 2008
DOR BioPharma Provides Update on orBec(R) European Regulatory and Development Strategy
DOR BioPharma Provides Update on orBec(R) European Regulatory and Development Strategy
HSMN NewsFeed - 8 May 2008
Osiris Receives Approval for Use of Prochymal(TM) Under FDA Expanded Access Treatment Program
Osiris Receives Approval for Use of Prochymal(TM) Under FDA Expanded Access Treatment Program
HSMN NewsFeed - 21 Apr 2008
Cerus Receives Label Expansion on CE Marks for Use of INTERCEPT Blood System
Cerus Receives Label Expansion on CE Marks for Use of INTERCEPT Blood System
HSMN NewsFeed - 15 Apr 2008
Kiadis Pharma Receives Orphan Drug Designation for Rhitol(TM) From the FDA
Kiadis Pharma Receives Orphan Drug Designation for Rhitol(TM) From the FDA
HSMN NewsFeed - 7 Dec 2007
DOR BioPharma Announces Results of orBec(R) End of Review Conference With the FDA
DOR BioPharma Announces Results of orBec(R) End of Review Conference With the FDA
HSMN NewsFeed - 9 Oct 2007
orBec(R) Clinical Summary Published in "Expert Opinion on Investigational Drugs"
orBec(R) Clinical Summary Published in "Expert Opinion on Investigational Drugs"
HSMN NewsFeed - 9 May 2007
FDA Advisory Panel Reviews DOR BioPharma's orBec(R) for Treatment of GI GVHD
FDA Advisory Panel Reviews DOR BioPharma's orBec(R) for Treatment of GI GVHD
HSMN NewsFeed - 4 Apr 2007
DOR BioPharma Announces Initiation of Clinical Development Program for Oral Leuprolide
DOR BioPharma Announces Initiation of Clinical Development Program for Oral Leuprolide
HSMN NewsFeed - 31 Jan 2007
FDA Advisory Committee to Review DOR BioPharma's orBec(R) for the Treatment of GI GVHD
FDA Advisory Committee to Review DOR BioPharma's orBec(R) for the Treatment of GI GVHD
HSMN NewsFeed - 12 Jan 2007
Pipex Pharmaceuticals Acquires Minority Interest in Its Effective Pharmaceuticals Subsidiary
Pipex Pharmaceuticals Acquires Minority Interest in Its Effective Pharmaceuticals Subsidiary
HSMN NewsFeed - 28 Nov 2006
European Medicines Agency Accepts DOR BioPharma's MAA Filing for orBec(R)
European Medicines Agency Accepts DOR BioPharma's MAA Filing for orBec(R)
HSMN NewsFeed - 7 Nov 2006
DOR BioPharma Submits European Marketing Application for orBec(R) to Treat GI Graft-Versus-Host Disease
DOR BioPharma Submits European Marketing Application for orBec(R) to Treat GI Graft-Versus-Host Disease
HSMN NewsFeed - 22 Sep 2006
DOR BioPharma Files New Drug Application with FDA to Market orBec for GI GVHD
DOR BioPharma Files New Drug Application with FDA to Market orBec for GI GVHD
Additional items found! 27

Members Archive contains
27 additional stories matching:
GvHD
(Password required)
GvHD
(Password required)